We’re conducting a study for patients interested in transitioning from Xyrem® to Xywav™, a new formula with less sodium.
The SEGUE Study is documenting the patient experience of changing from an approved medication, Xyrem® (sodium oxybate), to another approved medication, Xywav™ (calcium, magnesium, potassium, and sodium oxybates), for people with narcolepsy. The study medication, Xywav, has the same active ingredients as Xyrem, but a much lower amount of sodium.
Researchers are hoping to build on past clinical studies, by gathering more information on side effects and the effectiveness of switching from Xyrem to Xywav. The study will also look at whether changes need to be made to the dose of Xywav after switching.
You or someone you care for may be able to take part if you/they:
- Are 18–80 years of age
- Have a primary diagnosis of narcolepsy (not caused by another disease)
- Have been on a stable dose of Xyrem for more than 2 months.
If you take part, you will be in the SEGUE Study for up to 14 weeks. During this time, you will need to attend 7 study visits and have 2 telephone calls.
Are you ready to make the change from Xyrem® to Xywav™?
Want to know more? If you are interested in learning more about the SEGUE Study, please contact:
Meris Clinical Research